Summary: Therapixel has received two new FDA clearances for its updated MammoScreen, which integrates AI features like priors, case pre-check, and pre-reporting to improve efficiency, reduce radiologist fatigue, and increase accuracy in breast cancer screening.

Key Takeaways

  1. Therapixel’s updated MammoScreen, now FDA-cleared, incorporates AI features beyond lesion detection, including priors, case pre-check, and pre-reporting, to streamline the breast imaging process.
  2. The new version reduces radiologist fatigue by 40% and cuts reading time by up to 35% through features like worklist management and screening assessment using priors.
  3. These updates are designed to improve efficiency, accuracy, and streamline the breast cancer screening workflow for radiologists and healthcare teams.

———————————————————————————————————————————————————————————————

Therapixel has received two new U.S. FDA 510(k) clearances for its updated MammoScreen, an AI tool for breast cancer screening. The new version enhances the entire breast imaging process by integrating AI beyond lesion detection, including features such as priors, case pre-check, and pre-reporting. It also retains the MammoScreen Score to improve radiologists’ sensitivity and specificity.

The update includes worklist management with a complexity index to reduce radiologist fatigue by 40%, a case pre-check feature that provides patient health history upfront, and screening assessment using priors, which can reduce reading time by up to 35%. It also includes breast density assessment for mandatory reporting and a pre-reporting feature that automatically generates screening reports for validation.

Reducing Radiologist Fatigue and Streamlining Workflow

These new features, now available for clinical use, are designed to help radiologists work more efficiently and provide faster, more accurate results to patients, Therapixel officials say.

“Therapixel has consistently empowered radiologists to excel, ensuring women receive reassurance faster and with greater confidence,” says Matthieu Leclerc-Chalvet, CEO of Therapixel. “These major clearances and releases elevate MammoScreen to a comprehensive suite, assisting radiologists at every step of the breast cancer screening workflow, and providing a service unmatched in the industry. With these new features, radiologists can double their reading time savings compared to the previous version.”

What’s more, he says, “Radiologists will appreciate the reduced fatigue, administrators the improved efficiency and care consistency, and the IT team the seamless one-time installation. We’re proud to launch this new version of MammoScreen, once again delivering unparalleled value to radiologists and patients.”